



# Celebrating Cessation

Volume 2, Issue 6 July 2009

## Tobacco Cessation Program

Iowa/Nebraska Primary Care Association

### Newsletter Spotlight

#### Food and Drug Administration Given Authority to Regulate Tobacco Products

The Family Smoking Prevention and Tobacco Control Act, signed by President Obama on June 22, 2009, grants the U.S. Food and Drug Administration (FDA) authority to regulate the manufacturing, marketing, and sale of tobacco products. A new FDA Center for Tobacco Products was also established through the act. Some of the primary provision of the Act that the Center will oversee include:

Provision	Details
Tobacco Standards	Allows the FDA to require changes in current and future tobacco products, including the reduction or elimination of ingredients, additives, if the changes will protect public health. Gives the FDA authority to regulate nicotine yields.
Ingredient Disclosure	Requires tobacco companies to provide the FDA with a listing of all ingredients in their products, including additives, nicotine content, and smoke constituents.
Reduced Harm Claims	Bans the use of descriptors such as “light,” mild,” and “low” on labels on in advertising. Manufacturers must get approval before marketing or selling any product as a “modified risk” product.
Warning Labels	Requires warning labels that cover the top 50% of the front and rear panels of a cigarette pack and 20% of an advertisement area. Within 24 months, warning labels must also include color graphics depicting the negative health consequences of smoking.
Additive Restrictions	Prohibits the use of artificial or natural flavor other than menthol.
Research Disclosure	Requires tobacco companies to provide all of their research on the effects of tobacco products and marketing research.

Source: Adapted from CESAR from 111th Congress, *Family Smoking Prevention and Control Act*, H.R. 1256 (enacted), 2009. Available online at <http://hdl.loc.gov/uscongress/legislation.111HR1256>.

#### Please Share!

Please share any tools you have been developing to assess your patients' readiness to quit. Send them to Sarah at [sdixongale@ianepca.com](mailto:sdixongale@ianepca.com) by July 8. She will compile them and send them to the rest of the group!

Please also send two signed copies of the MOA Sarah distributed to each lead by July 10.

#### News

##### FDA Warning for Chantix and Zyban

On July 1, 2009, the FDA announced that it is requiring manufacturers to put a Boxed Warning on the prescribing information for the smoking cessation drugs Chantix (varenicline) and Zyban (bupropion). The warning will highlight the risk of serious mental health events including changes in behavior, depressed mood, hostility, and suicidal thoughts when taking these drugs.

**Please see the attachment in this email for more information on this warning.**

### Questions or Comments?

E-mail us at [sdixongale@ianepca.com](mailto:sdixongale@ianepca.com) or [kburgener@ianepca.com](mailto:kburgener@ianepca.com)  
Or Call 515-244-9610 and ask for Sarah or Kate